No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 17:18 (635 d 18:52 ago) – Posting: # 19813
Views: 1,557

Dear yuvaneshwari,

» Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

» In the above scenario, can we consider for BCS based waiver approach ?

I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.


Complete thread:

 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 6 (0 registered, 6 guests [including 3 identified bots]).
Forum time: Saturday 12:10 UTC (Europe/Vienna)

It is the peculiar and perpetual error of the human understanding
to be more moved and excited by affirmatives than negatives.    Francis Bacon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz